Qilian International Holding Group Limited Enters into Exclusive Agency Agreement with Kangzhiyuan to Boost Sales of Gan Di X...
05 Maggio 2021 - 2:00PM
Qilian International Holding Group Limited (Nasdaq: QLI) (the
“Company”), a China-based pharmaceutical and chemical products
manufacturer, today announced that the Company, through its
subsidiary Gansu Qilianshan Pharmaceutical Co., Ltd., has entered
into an exclusive agency agreement (the "Agreement") with Henan
Kangzhiyuan Pharmaceutical Co., Ltd. ("Kangzhiyuan"), a
pharmaceutical company with omni-channel in China, to boost the
sales of Gan Di Xin® product of Compound Licorice Lozenges (the
“Product”). The agreement was signed on April 22, 2021 with an
initial period of five years.
Pursuant to the Agreement, both parties agree to
cooperate in product marketing of Gan Di Xin® through leveraging
their advantages and resources. The Company agrees to engage
Kangzhiyuan as the exclusive sales agent for distributing the
Company’s licorice products.
The Company has independently researched and
developed the Product, which has become a well-known national
chemical product and a brand-name product in Gansu provenience. Gan
Di Xin® is an innovative antitussive and expectorant medicine made
from high-quality raw licorice materials sourced from Northwest
China, which the Company manufactures with its patented
purification, thin-film coating and inclusion technology, allowing
patients to more easily administer the medication. In addition, Gan
Di Xin® has unparalleled taste and efficacy compared with
traditional antitussive and expectorant drugs, making it an
upgraded product among similar drugs.
Mr. Zhanchang Xin, Chairman and CEO of the
Company, commented, “We are very pleased to cooperate with
Kangzhiyuan. Previously, we marketed Gan Di Xin® mainly through
third-party platforms in towns such as healthcare centers,
individual clinics, and pharmacies. We believe the national
marketing channels and sales network of Kangzhiyuan will greatly
assist us in achieving record sales for the compound licorice
lozenges product. We look forward to working with Kangzhiyuan in
accelerating the promotion of the Product to the domestic
market.”
About Qilian International Holding Group
LimitedQilian International Holding Group Limited,
headquartered in Gansu, China, is a pharmaceutical and chemical
products manufacturer in China. It focuses on the development,
manufacture, marketing and sale of licorice products,
oxytetracycline products, traditional Chinese medicine derivatives
product, heparin product, sausage casings, and fertilizers. The
Company’s products are sold in more than 20 provinces in China. For
more information, visit the company’s website
at http://ir.qlsyy.net/.
Forward-Looking StatementsThis
announcement contains forward-looking statements within the meaning
of the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. All statements other than statements of
historical fact in this announcement are forward-looking
statements. These forward-looking statements involve known and
unknown risks and uncertainties and are based on current
expectations and projections about future events and financial
trends that the Company believes may affect its financial
condition, results of operations, business strategy and financial
needs. Investors can identify these forward-looking statements by
words or phrases such as "may," "will," "expect," "anticipate,"
"aim," "estimate," "intend," "plan," "believe," "potential,"
"continue," "is/are likely to" or other similar expressions. The
Company undertakes no obligation to update forward-looking
statements to reflect subsequent occurring events or circumstances,
or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in
these forward-looking statements are reasonable, it cannot assure
you that such expectations will turn out to be correct, and the
Company cautions investors that actual results may differ
materially from the anticipated results and encourages investors to
review other factors that may affect its future results in the
Company’s registration statement and in its other filings with the
SEC.
For more information, please contact:Qilian
International Holding Group LimitedEmail: ir@qlsyy.netAscent
Investors Relations LLCTina XiaoPresidentPhone:
917-609-0333Email: tina.xiao@ascent-ir.com
Grafico Azioni Qilian (NASDAQ:QLI)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Qilian (NASDAQ:QLI)
Storico
Da Lug 2023 a Lug 2024